INS and type 2 diabetes mellitus: Furthermore, DPP-4 inhibitors augment insulin secretion and increase β-cell mass by stimulating β-cell differentiation and proliferation by reducing oxidative and endoplasmic reticulum stress, inflammation, and apoptosis both in vitro and in pre-clinical models of T2D [11–15].